<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245410</url>
  </required_header>
  <id_info>
    <org_study_id>UE-CHUB 001-2020</org_study_id>
    <nct_id>NCT04245410</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma</brief_title>
  <acronym>PANMEKID</acronym>
  <official_title>Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Extremadura</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Extremadura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic metastases are a rare entity. In cases of metastatic renal carcinoma (RCC) it can&#xD;
      present as isolated pancreatic metastasis, considering the possibility of surgical resection.&#xD;
&#xD;
      Goals:&#xD;
&#xD;
        -  Define survival after resection of pancreatic cancer metastases renal in a wide range of&#xD;
           our country.&#xD;
&#xD;
        -  Identify predictive survival factors&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Retrospective multicenter study in which cases of pancreatic resection due to renal cancer&#xD;
      metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      Pancreatic metastases are a rare entity and often synonymous with broader dissemination.&#xD;
      However, in cases of metastatic renal carcinoma (RCC) it can present as isolated pancreatic&#xD;
      metastasis, considering the possibility of surgical resection. Most of the literature refers&#xD;
      to isolated cases or short series, with the Johns Hopkins Hospital series being the largest&#xD;
      in a single published center (1,2). In all of them, survival after resection is prolonged.&#xD;
&#xD;
      Recently, due to the results obtained with the tyrosine kinase inhibitor drugs, the value of&#xD;
      resection of metastases of RCC origin has been questioned in an Italian multicenter study&#xD;
      (3), although other studies consider that resection can improve the prognosis if It is&#xD;
      associated with these drugs (4).&#xD;
&#xD;
      Justification:&#xD;
&#xD;
      The existing literature is limited to short series or mostly isolated cases. There are no&#xD;
      clear prognostic factors that are limited in most cases to being merely descriptive studies.&#xD;
&#xD;
      Goals:&#xD;
&#xD;
        -  Define survival after resection of pancreatic cancer metastases renal in a wide range of&#xD;
           our country.&#xD;
&#xD;
        -  Identify predictive survival factors that allow establishing Subgroups of patients with&#xD;
           the greatest benefit after surgery or, conversely, those who potentially do not benefit&#xD;
           from drug treatment.&#xD;
&#xD;
      Method:&#xD;
&#xD;
      Retrospective multicenter study in which cases of pancreatic resection due to renal cancer&#xD;
      metastases are collected until December 2019, identified by each of the centers included in&#xD;
      the study. A data collection sheet has been designed for each case that will be sent to the&#xD;
      participating centers. To know which centers could have performed some pancreatic resection&#xD;
      due to renal cancer metastases, an email has been sent to all members of the Spanish&#xD;
      association of surgeons and Spanish members of International Hepato-pancreatic and biliary&#xD;
      surgery association and this information has been included on their websites. The study&#xD;
      variables include those related to demographic data of the patient, with the primary tumor,&#xD;
      with the presentation of pancreatic metastasis, pancreas surgery and short-term and long-term&#xD;
      postoperative follow-up.&#xD;
&#xD;
      Statistic analysis The data will be analyzed using the IBM SPSS Statistics for Mac version&#xD;
      22.0 program (IBM Corp., Orchard Road Armonk, New York, US). Student's t, Mann Whitney U,&#xD;
      Chi-square, or Fisher's test will be used according to the parameters studied. Categorical&#xD;
      data will be presented as frequency and percentage. Continuous data will be presented as mean&#xD;
      and standard deviation or median and interquartile range depending on the distribution of the&#xD;
      data. Subgroups created to compare characteristics and results will be measured using Mann&#xD;
      Whitney U, Chi-square or Kruskal Wallis test. A p &lt;0.05 will be considered statistically&#xD;
      significant.&#xD;
&#xD;
      Limitations of the study:&#xD;
&#xD;
      The main limitation is the retrospective and multicenter nature that can lead to selection or&#xD;
      information bias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Overall survival (months) from surgical resection of pancreatic metastases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Disease free survival (months) from surgical resection of pancreatic metastases</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Surgical Procedure</condition>
  <condition>Disease Free Survival</condition>
  <condition>Overall Survival</condition>
  <arm_group>
    <arm_group_label>Patients surgically treated of pancreatic metastases from RCC</arm_group_label>
    <description>Patients surgically treated of pancreatic metastases from renal cell carcinoma. Pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy are included.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients operated from renal cell carcinoma in the past that have developed pancreatic&#xD;
        metastases. They are included in the study after pancreatic resection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with resecable pancreatic metastases from RCC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unresecable pancreatic metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerardo Blanco-Fernandez, MD</last_name>
    <phone>0034924218022</phone>
    <email>gerardoblanco@unex.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gerardo Blanco-Fernández</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Blanco-Fernández, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Tosoian JJ, Cameron JL, Allaf ME, Hruban RH, Nahime CB, Pawlik TM, Pierorazio PM, Reddy S, Wolfgang CL. Resection of isolated renal cell carcinoma metastases of the pancreas: outcomes from the Johns Hopkins Hospital. J Gastrointest Surg. 2014 Mar;18(3):542-8. doi: 10.1007/s11605-013-2278-2. Epub 2013 Oct 26.</citation>
    <PMID>24163138</PMID>
  </reference>
  <reference>
    <citation>Lee SR, Gemenetzis G, Cooper M, Javed AA, Cameron JL, Wolfgang CL, Eckhauser FE, He J, Weiss MJ. Long-Term Outcomes of 98 Surgically Resected Metastatic Tumors in the Pancreas. Ann Surg Oncol. 2017 Mar;24(3):801-807. doi: 10.1245/s10434-016-5619-z. Epub 2016 Oct 21.</citation>
    <PMID>27770346</PMID>
  </reference>
  <reference>
    <citation>Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol. 2015;22(6):2094-100. doi: 10.1245/s10434-014-4256-7. Epub 2014 Dec 4.</citation>
    <PMID>25472645</PMID>
  </reference>
  <reference>
    <citation>Chang YH, Liaw CC, Chuang CK. The role of surgery in renal cell carcinoma with pancreatic metastasis. Biomed J. 2015 Mar-Apr;38(2):173-6. doi: 10.4103/2319-4170.137771.</citation>
    <PMID>25179721</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 25, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Extremadura</investigator_affiliation>
    <investigator_full_name>Gerardo Blanco-Fernández</investigator_full_name>
    <investigator_title>Head of Surgery, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Pancreatic metastases</keyword>
  <keyword>Resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

